

# Pieter J Colin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8912278/publications.pdf>

Version: 2024-02-01

55  
papers

1,998  
citations

394421

19  
h-index

254184

43  
g-index

57  
all docs

57  
docs citations

57  
times ranked

2445  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dexmedetomidine Clearance Decreases with Increasing Drug Exposure: Implications for Current Dosing Regimens and Target-controlled Infusion Models Assuming Linear Pharmacokinetics. <i>Anesthesiology</i> , 2022, 136, 279-292.	2.5	7
2	Mechanism-based pharmacodynamic model for propofol haemodynamic effects in healthy volunteers. <i>British Journal of Anaesthesia</i> , 2022, 128, 806-816.	3.4	11
3	Resisting neural inertia: an exercise in floccinaucinihilipilification?. <i>British Journal of Anaesthesia</i> , 2021, 126, 31-34.	3.4	2
4	Comment on Morse et al. A Universal Pharmacokinetic Model for Dexmedetomidine in Children and Adults. <i>J. Clin. Med.</i> 2020, 9, 3480. <i>Journal of Clinical Medicine</i> , 2021, 10, 3003.	2.4	1
5	Optimizing Amoxicillin/Clavulanic Acid Dosing Regimens in Patients on Maintenance High-Flux Hemodialysis. <i>American Journal of Kidney Diseases</i> , 2021, 78, 153-156.	1.9	2
6	Clinical validation of pharmacokinetic/pharmacodynamic models for propofol infusion. Response to <i>Br J Anaesth</i> 2021: 126: e172-4. <i>British Journal of Anaesthesia</i> , 2021, 127, e3-e5.	3.4	2
7	Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment. <i>British Journal of Anaesthesia</i> , 2021, 127, 415-423.	3.4	75
8	Do Vancomycin Pharmacokinetics Differ Between Obese and Non-obese Patients? Comparison of a General-Purpose and Four Obesity-Specific Pharmacokinetic Models. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 126-130.	2.0	7
9	Target-controlled-infusion models for remifentanyl dosing consistent with approved recommendations. <i>British Journal of Anaesthesia</i> , 2020, 125, 483-491.	3.4	25
10	PKPD Modeling and Dosing Considerations in Advanced Ovarian Cancer Patients Treated with Cisplatin-Based Intraoperative Intraperitoneal Chemotherapy. <i>AAPS Journal</i> , 2020, 22, 96.	4.4	9
11	Genetic Algorithms as a Tool for Dosing Guideline Optimization: Application to Intermittent Infusion Dosing for Vancomycin in Adults. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2020, 9, 294-302.	2.5	1
12	Influence of an "Electroencephalogram-Based" Monitor Choice on the Delay Between the Predicted Propofol Effect-Site Concentration and the Measured Drug Effect. <i>Anesthesia and Analgesia</i> , 2020, 131, 1184-1192.	2.2	5
13	Saturable elimination of piperacillin in critically ill patients: implications for continuous infusion. <i>International Journal of Antimicrobial Agents</i> , 2019, 54, 741-749.	2.5	14
14	Model-based analysis of treatment effects of paclitaxel microspheres in a microscopic peritoneal carcinomatosis model in mice. <i>Pharmaceutical Research</i> , 2019, 36, 127.	3.5	12
15	A semiphysiological population pharmacokinetic model of agomelatine and its metabolites in Chinese healthy volunteers. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 1003-1014.	2.4	5
16	Target-Controlled Infusion of Cefepime in Critically Ill Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2019, 64, .	3.2	8
17	Pharmacodynamic Interaction of Remifentanyl and Dexmedetomidine on Depth of Sedation and Tolerance of Laryngoscopy. <i>Anesthesiology</i> , 2019, 131, 1004-1017.	2.5	28
18	Population Pharmacodynamics of Propofol and Sevoflurane in Healthy Volunteers Using a Clinical Score and the Patient State Index. <i>Anesthesiology</i> , 2019, 131, 1223-1238.	2.5	17

#	ARTICLE	IF	CITATIONS
19	Population pharmacokinetics and evaluation of the predictive performance of pharmacokinetic models in critically ill patients receiving continuous infusion meropenem: a comparison of eight pharmacokinetic models. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 432-441.	3.0	43
20	Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 667-674.	3.0	22
21	Vancomycin Pharmacokinetics Throughout Life: Results from a Pooled Population Analysis and Evaluation of Current Dosing Recommendations. <i>Clinical Pharmacokinetics</i> , 2019, 58, 767-780.	3.5	57
22	Switchability of Gabapentin Formulations: A Randomized Trial to Assess Bioequivalence Between Neurontin and Gabasandoz on the Individual Subject Level. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 195-203.	4.7	9
23	Target-Controlled Continuous Infusion for Antibiotic Dosing: Proof-of-Principle in an In-silico Vancomycin Trial in Intensive Care Unit Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1435-1447.	3.5	20
24	Pharmacokinetic-pharmacodynamic model for propofol for broad application in anaesthesia and sedation. <i>British Journal of Anaesthesia</i> , 2018, 120, 942-959.	3.4	168
25	Test of neural inertia in humans during general anaesthesia. <i>British Journal of Anaesthesia</i> , 2018, 120, 525-536.	3.4	41
26	A cross-sectional pilot study of student's proactive behavior in midwifery education: Validation of a developed questionnaire. <i>Nurse Education Today</i> , 2018, 62, 22-29.	3.3	8
27	A Physiologically Based Pharmacokinetic Perspective on the Clinical Utility of Albumin-Based Dose Adjustments in Critically Ill Patients. <i>Clinical Pharmacokinetics</i> , 2018, 57, 59-69.	3.5	7
28	A dried blood spot assay for paclitaxel and its metabolites. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2018, 148, 307-315.	2.8	23
29	Proficiency Testing for Meropenem and Piperacillin Therapeutic Drug Monitoring: Preliminary Results From the Belgian Society on Infectiology and Clinical Microbiology Pharmacokinetic-Pharmacodynamic Working Group. <i>Therapeutic Drug Monitoring</i> , 2018, 40, 156-158.	2.0	6
30	Pharmacokinetic Pharmacodynamic Perspective on the Detection of Signs of Neural Inertia in Humans. <i>Anesthesiology</i> , 2018, 129, 373-375.	2.5	5
31	Clinical Pharmacokinetics and Pharmacodynamics of Dexmedetomidine. <i>Clinical Pharmacokinetics</i> , 2017, 56, 893-913.	3.5	639
32	Electrospray ionization mass spectrometry for the hydrolysis complexes of cisplatin: implications for the hydrolysis process of platinum complexes. <i>Journal of Mass Spectrometry</i> , 2017, 52, 434-441.	1.6	9
33	Zwitterionic hydrophilic interaction liquid chromatography-tandem mass spectrometry with HybridSPE-precipitation for the determination of intact cisplatin in human plasma. <i>Talanta</i> , 2017, 174, 171-178.	5.5	16
34	Dexmedetomidine pharmacodynamics in healthy volunteers: 2. Haemodynamic profile. <i>British Journal of Anaesthesia</i> , 2017, 119, 211-220.	3.4	50
35	Dexmedetomidine pharmacokinetic-pharmacodynamic modelling in healthy volunteers: 1. Influence of arousal on bispectral index and sedation. <i>British Journal of Anaesthesia</i> , 2017, 119, 200-210.	3.4	61
36	Performance of the Eleveld pharmacokinetic model to titrate propofol in an obese Japanese patient population. <i>European Journal of Anaesthesiology</i> , 2016, 33, 58.	1.7	7

#	ARTICLE	IF	CITATIONS
37	Antimicrobial Effect of a Single Dose of Amoxicillin on the Oral Microbiota. <i>Clinical Implant Dentistry and Related Research</i> , 2016, 18, 699-706.	3.7	7
38	What about confidence intervals? A word of caution when interpreting PTA simulations. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2502-2508.	3.0	14
39	Effects of Food and Pharmaceutical Formulation on Desmopressin Pharmacokinetics in Children. <i>Clinical Pharmacokinetics</i> , 2016, 55, 1159-1170.	3.5	15
40	Community pharmacists's™ evaluation of potentially inappropriate prescribing in older community-dwelling patients with polypharmacy: observational research based on the GheOPAS tool. <i>Journal of Public Health</i> , 2016, 39, 583-592.	1.8	16
41	A model-based analysis of the predictive performance of different renal function markers for cefepime clearance in the ICU. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 2538-2546.	3.0	15
42	Disulfiram inhibition of cyanide formation after acetonitrile poisoning. <i>Clinical Toxicology</i> , 2016, 54, 56-60.	1.9	3
43	Propofol Breath Monitoring as a Potential Tool to Improve the Prediction of Intraoperative Plasma Concentrations. <i>Clinical Pharmacokinetics</i> , 2016, 55, 849-859.	3.5	30
44	The interchangeability of gabapentin 800 mg tablets: a randomized, controlled trial to establish individual bioequivalence. <i>Clinical Therapeutics</i> , 2015, 37, e33.	2.5	0
45	Potentially inappropriate prescribing in community-dwelling older people across Europe: a systematic literature review. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 1415-1427.	1.9	226
46	Physiology-Based IVIVE Predictions of Tramadol from in Vitro Metabolism Data. <i>Pharmaceutical Research</i> , 2015, 32, 260-274.	3.5	19
47	Moxifloxacin dosing in post-€bariatric surgery patients. <i>British Journal of Clinical Pharmacology</i> , 2014, 78, 84-93.	2.4	6
48	A Model Based Analysis of IPEC Dosing of Paclitaxel in Rats. <i>Pharmaceutical Research</i> , 2014, 31, 2876-2886.	3.5	11
49	Quantification of cytochrome 2E1 in human liver microsomes using a validated indirect ELISA. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2014, 88, 536-541.	2.8	0
50	Enzymatic tumour tissue digestion coupled to SPE-€UPLC-€Tandem Mass Spectrometry as a tool to explore paclitaxel tumour penetration. <i>Talanta</i> , 2014, 129, 119-125.	5.5	4
51	Development and validation of a fast and uniform approach to quantify Î²-lactam antibiotics in human plasma by solid phase extraction-liquid chromatography-€electrospray-tandem mass spectrometry. <i>Talanta</i> , 2013, 103, 285-293.	5.5	95
52	Oral bioavailability of moxifloxacin after Roux-en-Y gastric bypass surgery. <i>Journal of Antimicrobial Chemotherapy</i> , 2012, 67, 226-229.	3.0	25
53	Development of a Nanocrystalline Paclitaxel Formulation for Hipec Treatment. <i>Pharmaceutical Research</i> , 2012, 29, 2398-2406.	3.5	37
54	Development and validation of a fast and sensitive UPLC-€MS/MS method for the quantification of six probe metabolites for the in vitro determination of cytochrome P450 activity. <i>Talanta</i> , 2012, 89, 209-216.	5.5	43

#	ARTICLE	IF	CITATIONS
55	Development and validation of an enzyme-linked immunosorbent assay for the quantification of cytochrome 3A4 in human liver microsomes. <i>Talanta</i> , 2012, 99, 357-362.	5.5	7